Ann: CANNTAB GRANTED AUSTRALIAN PATENT, page-56

Cheers @Rev1, (sorry needed to change my first response)

"Is there any place in Australia that we can produce pills and tablets locally?"

The answer is Yes, there are facilities here that can do that for you at GMP quality level. Some potential roadblocks still:

1) We are still in our infancy/prove up period, and there are, as we would expect, supply (flower) and quality issues. Canada approved medicinal Cannabis in 2001; Australia in 2016.
2) I believe that the the Australian industry is still working out its cultivation/production cost ratios and building its customer base to grow enough Cannabis to ensure consistency in active compound efficacy levels.
3) Logistic costs appear to still be high in Australia (state to state movement of raw seed) until there is enough raw product being grown to ensure that you have your cultivation/manufacturing/GMP pill production all housed on one site. I don't believe that there are many of those facilities yet set up in Australia.

"Why does it have to be Canntab?"

CannTab is the only company that has so far produced and patented a unique pharma-grade regulated micro dosage Cannabis pill anywhere in the world, as I understand it.

"Why do we have to get our "Australian patent" exposed to a foreign company?"

The patent is CannTab's not CGB's. We get to benefit from the 50/50 partnership and distributor rights.

"Why do we have to add in the cost of import and export and waiting time, etc.?"

I am a firm believer that you have one shot at making a good impression, and so I think it is more sensible if the costs related to the rollout of the first product for CGB comes directly from CannTab itself.

As to why CGB possibly changed to importation may also be due to the massive cost blowouts experienced by other Cannabis companies here in Australia, growing and producing enough flower/oil to make pharma-grade tablets, which logically would make the first batch of tablets quite expensive to the consumer. There is no guarantee that we would not have production cost overruns and failures ourselves, as we have already seen with Aussie companies over these past 3 years. CGB also had its own crop failures with the drought.

"If the pills and tablets will also be distributed in the USA, Canada, EU, will the profit also be shared (as even)?"

We only have Australia and first dibs in Asia. I believe that all profits, after costs, are split 50/50.

From a media review on CannTab's ultimate goal for their business model.

"In global terms, Canntab sees growth prospects in Canada, the United States (where it recently won patents) and Europe. An existing deal with an Australian company has already staked a claim in that market. Still, the real advantage of doing international licensing deals is where the company could license their tech to others, receive a royalty, and not have to outlay any capital or take expansion risk."

https://equity.guru/2021/03/03/cann...e-as-cbd-caplets-shipped-to-medipharm-labs-t/


Cheers...59